The efficacy and safety of taletrectinib in patients with TKI-naive or crizotinib-pretreated ROS1-positive non-small cell lung cancer (NSCLC).-MedSci.cn

The efficacy and safety of taletrectinib in patients with TKI-naive or crizotinib-pretreated ROS1-positive non-small cell lung cancer (NSCLC).

Li, W; Yang, N; Ma, HW; Fan, HJ; Li, KY; Wu, HJ; Yu, Q; Wang, YS; Meng, X; Wang, XC; Qin, XT; Wang, ZP; Liu, YP; Tao, M; Zhuang, W; Fang, Y; Sun, P; Lu, KH; Wu, JX; Zhou, CC

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务